We are live on ! Find out more
AAPG

Ascentage Pharma

14.86 USD
-0.37
2.43%
At close Updated Sep 25, 4:00 PM EDT
1 day
-2.43%
5 days
-6.6%
1 month
-11.49%
3 months
-12.84%
6 months
-33.6%
Year to date
-43.65%
1 year
-60.72%
5 years
-14.5%
10 years
-14.5%
 

About: Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.

Employees: 828

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 18.2%
Neutral 81.8%
Negative 0%
Neutral
GlobeNewsWire
24 days ago
Ascentage Pharma to Participate in Four Upcoming Investor Conferences
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate in four upcoming investor conferences in New York, New York.
Ascentage Pharma to Participate in Four Upcoming Investor Conferences
Neutral
Seeking Alpha
1 month ago
Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript
Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript
Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript
Neutral
MarketBeat
1 month ago
Ascentage Pharma Group International H1 Earnings Call Highlights
Ascentage Pharma Group International NASDAQ: AAPG reported first-half 2026 revenue growth as it continued investing in global registrational studies for its hematology-oncology pipeline and began building commercial capabilities outside China.
Ascentage Pharma Group International H1 Earnings Call Highlights
Neutral
GlobeNewsWire
1 month ago
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
Revenue for the first half of 2026 increased 29% year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr.
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
Neutral
GlobeNewsWire
1 month ago
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate in the Evercore ISI 2nd Annual China Biotech Summit, being held August 17-19, 2026 at The Ritz-Carlton Shanghai, Pudong.
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
Neutral
GlobeNewsWire
1 month ago
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
In a release issued under the same headline earlier today by Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), please note that in the first paragraph of the release, the time should be 7:00 am Eastern Daylight Time (EDT) on August 19, 2026 / 7:00 pm Hong Kong Time (HKT) and not 9 am EDT and 9 pm HKT as previously stated. The corrected release follows:
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
Neutral
GlobeNewsWire
1 month ago
Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
ROCKVILLE, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that it will release its six months 2026 unaudited interim results and provide business updates at 9:00 am Eastern Daylight Time (EDT) on August 19, 2026 / 9:00 pm Hong Kong Time (HKT) on August 19, 2026.
Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
Neutral
GlobeNewsWire
1 month ago
Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
ROCKVILLE, Md., Aug. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced the appointment of Faiçal Miyara, PhD, as Chief Business Officer (CBO), responsible for the Company's global business development, and Jim Ziegler as Chief Commercial Officer (CCO), responsible for the commercialization of the Company's products in the United States and other countries outside of China.
Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts Predict a 160.09% Upside in Ascentage Pharma Group International - Unsponsored ADR (AAPG): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 160.1% in Ascentage Pharma Group International - Unsponsored ADR (AAPG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Predict a 160.09% Upside in Ascentage Pharma Group International - Unsponsored ADR (AAPG): Here's What You Should Know
Neutral
GlobeNewsWire
2 months ago
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
ROCKVILLE, Md. and SUZHOU, China, July 26, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced that its Chairman and Chief Executive Officer, Dr. Dajun Yang, has been named to The Medicine Maker Power List 2026, ranking No.
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
Price charts implemented using Lightweight Charts™